Xencor Inc

Xencor maintains a capital structure characterized by low leverage and high liquidity relative to its asset base. The company holds $14.2 million in cash and equivalents against $82.1 million in long-term debt, resulting in a debt-to-equity ratio of 0.16. Despite the negative net cash position flagged in risk assessments, the current ratio stands at 6.57, indicating strong short-term solvency. The market capitalization is $1.46 billion, trading at a price-to-book ratio of 2.86. The company reported a net loss of $128.9 million in Q1 2026, driven by operating losses and significant non-cash charges, including a $51.9 million loss on equity securities.

Profitability metrics reflect the pre-commercial stage of the business, with a return on equity of -17.8% and return on assets of -12.5%. Operating expenses totaled $82.4 million in Q1 2026, comprising $64.7 million in research and development and $17.7 million in general and administrative costs. Revenue was $4.5 million, primarily from collaborations, milestones, and royalties, a significant decline from $32.7 million in the same period of the prior year. The company’s free cash flow was negative $68.2 million, consistent with its heavy investment in R&D and lack of product sales.

Revenue concentration is high, derived entirely from licensing and collaboration agreements with major pharmaceutical partners. Key partners identified in filings include Alexion, Amgen, Gilead, Janssen Biotech, Novartis, and MorphoSys. The revenue mix is volatile, dependent on milestone achievements and royalty accruals rather than steady product sales. In Q1 2026, revenue dropped sharply compared to the prior year, highlighting the lumpy nature of collaboration-based income. There is no disclosed geographic breakdown of revenue, but the company is headquartered in the United States and partners with global entities.

The growth trajectory is defined by clinical development milestones rather than top-line revenue expansion. Q1 2026 revenue of $4.5 million represents a 86% year-over-year decline from $32.7 million in Q1 2025. Operating losses widened from $43.2 million to $77.9 million year-over-year. The company continues to invest heavily in its pipeline, including programs like XmAb819, XmAb657, and XmAb942. The negative cash flow from operations of $67.6 million underscores the ongoing capital intensity required to advance these candidates through clinical trials.

Risk factors include medium liquidity risk due to negative net cash and high burn rate, though mitigated by a strong current ratio. Dilution risk is assessed as low, with only $0.95 million in proceeds from stock option exercises in Q1 2026. Key flags include the restatement of financial statements due to internal control weaknesses and the potential for additional material weaknesses. The company faces significant competition in the pharmaceutical industry and relies on the success of its partners’ clinical trials and regulatory approvals.

Recent events include a notable stock price increase of 10.42% in a single day on July 21, 2026, with volume 1.38x the 20-day average. Analyst sentiment remains positive, with a mean recommendation of 1.86 (buy) and a mean price target of $29.64, implying upside from the current price of $19.44. The company disclosed forward-looking statements regarding the impact of inflation, clinical trial success, and regulatory approvals. Filing observations note the evaluation of Alexion’s notice regarding variable consideration constraints and royalty guidance.

Analysts project 52.5% upside to a mean price target of $29.64, reflecting strong buy consensus among 14 analysts.

The company maintains a healthy current ratio of 6.25, indicating strong short-term liquidity to meet immediate obligations.

Debt-to-equity ratio of 0.16 sits above the cohort median, suggesting a conservative capital structure relative to peers.

Cash conversion metrics rank above the cohort median, indicating relatively efficient cash generation compared to pharmaceutical peers.

Dilution risk is assessed as low, providing some protection for existing shareholders against immediate equity erosion.

Revenue declined 19% annually from FY2023 to FY2025, signaling a significant contraction in top-line growth trajectory.

Operating and net margins rank in the bottom quartile of the pharmaceutical cohort, showing poor relative profitability.

Revenue $4.5M; Operating income -$77.9M.

• ▍Revenue $4.5M
• ▍Operating income -$77.9M
• ▍Net margin -2854.7%

Revenue $97.3M; Operating income -$123.9M.

• ▍Revenue $97.3M
• ▍Operating income -$123.9M
• ▍Net margin -87.6%

Revenue $76.3M; Operating income -$76.4M.

• ▍Revenue $76.3M
• ▍Operating income -$76.4M
• ▍Net margin -103.8%

Revenue $125.6M; Operating income -$177.5M.

• ▍Revenue $125.6M
• ▍Operating income -$177.5M
• ▍Net margin -73.2%

Revenue $110.5M; Operating income -$178.4M.

• ▍Revenue $110.5M
• ▍Operating income -$178.4M
• ▍Net margin -210.5%

Revenue $110.5M; Operating income -$178.4M.

• ▍Revenue $110.5M
• ▍Operating income -$178.4M
• ▍Net margin -210.5%

Revenue $168.3M; Operating income -$138.6M.

• ▍Revenue $168.3M
• ▍Operating income -$138.6M
• ▍Net margin -74.9%

Revenue $174.6M; Operating income -$132.4M.

• ▍Revenue $174.6M
• ▍Operating income -$132.4M
• ▍Net margin -76.2%